Ductal Carcinoma In Situ of the Breast: Perspectives on Tumor Subtype and Treatment

Abstract EN

Objective.

To evaluate ductal carcinoma in situ (DCIS) characteristics and the effect of different treatment strategies.

Patients and Methods.

Using data with known hormone receptor (HoR) and human epidermal growth factor receptor 2 (HER2) status obtained by the Surveillance, Epidemiology, and End Results (SEER) program from 2010-2014, the study was conducted to investigate tumor subtype-specific differences in various characteristics, overall survival (OS), and breast cancer-specific mortality (BCSM).

Results.

A total of 3415 patients with DCIS were eligible.

Compared with HoR+/HER- subgroup, patients with triple-negative (TN) and HoR-/HER+ were commonly higher in grade, larger in size, and tended to receive mastectomy (P<0.05).

The multivariate analysis revealed that patients with TN were more likely to have a poorer OS and show a higher breast cancer-specific mortality compared with the HoR+/HER- subgroup (P<0.05).

Multivariate analysis on the history of local treatment and surgery showed patients receiving breast-conserving surgery (BCS) plus radiotherapy (R) and BCS plus axillary lymph node dissection was likely to improve OS without affecting breast cancer-specific mortality (P<0.05).

Conclusion.

The results demonstrate that DCIS associated with TN subtype portends poor prognosis.

Meanwhile, BCS plus R was a preferable option and resulted in survival rates better than those achieved with mastectomy, and SLNB should be considered as an appropriate assessment of axillary staging in patients with DCIS.